What Bios Partners does

Bios Partners is a Fort Worth, Texas-based life sciences venture capital firm operating under the legal name Bios Equity Partners, LP. Founded in 2017, the firm identifies and invests in clinical-stage and preclinical biotechnology companies in the Central United States, a region it argues is systematically underfunded relative to the volume of NIH-funded science generated there. The firm's proprietary investment thesis quantifies this geographic opportunity using NIH data showing $3.36 of NIH funding per $1 of venture capital in the Central US versus $0.57 in the Western US.

The firm manages a portfolio of 14 active companies spanning multiple therapeutic modalities including advanced small molecules, gene therapy, engineered cell therapy, AI-driven drug development, medical devices, recombinant proteins, and macrophage immunotherapy. Notable portfolio companies include publicly listed entities such as Lantern Pharma (NASDAQ: LTRN), Taysha Gene Therapies (NASDAQ: TSHA), Cognition Therapeutics (NASDAQ: CGTX), IN8bio (NASDAQ: INAB), Opus Genetics (NASDAQ: IRD), Actuate Therapeutics (NASDAQ: ACTU), and Rein Therapeutics (NASDAQ: RNTX), as well as exited portfolio company Encore Vision (acquired by Novartis).

Bios Partners generates revenue through the standard venture capital model: management fees on committed capital from limited partners and carried interest from successful portfolio exits. Deal sourcing is network-driven, leveraging founding partners' memberships in Cowtown Angels, a Fort Worth-based angel investment network, and the firm's affiliated entity Bios Research, which provides proprietary fundamental healthcare industry research. The nine-person team combines 80-90+ years of experience across hedge funds, private equity, clinical drug development, and public pharma/biotech analysis, with a stated track record of leading 19 drugs from development into the clinic.

Name

Bios Partners

Legal name

Bios Equity Partners, LP

Website

https://biospartners.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Bios Partners is a Fort Worth, Texas-based life sciences venture capital firm that invests in clinical-stage and preclinical biotech companies in the Central United States. It manages 14 portfolio companies across gene therapy, cell therapy, AI-driven drug development, and medical devices, generating returns through management fees and carried interest.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Life Sciences & Biotech (R&D/Clinical) Staffing (BPACADAL)

Keywords

• Venture capital services
• Life sciences investing
• Biotech venture funding
• Early stage healthcare
• Portfolio company management

Headquarters

HQ city

Fort Worth

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Management Fees: VC firms typically charge management fees on committed capital from limited partners (LPs). The firm manages investments in portfolio companies.
2. Carried Interest: VC firms typically earn carried interest (a share of profits) from successful portfolio company exits. This is the primary upside for venture capital firms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Bios Partners is a life sciences venture capital firm that identifies and invests in advanced biotechnology companies in overlooked and under-invested markets in the Central United States. The firm provides equity capital and active operational support to clinical-stage and preclinical biotech companies developing therapeutics across small molecules, gene therapy, cell therapy, medical devices, recombinant proteins, and AI-driven drug discovery, and generates returns through management fees from limited partners and carried interest from portfolio exits.

Product overview

Bios Partners is a life sciences venture capital firm providing investment services to identify and cultivate advanced biotech companies in overlooked Central U.S. markets. The firm offers a unified investment platform that combines geographic disruption strategy with active company cultivation, leveraging 90+ years of combined experience in hedge funds, private equity, clinical drug development, and pharma/biotech analysis. The portfolio spans multiple therapeutic modalities including advanced small molecules (Actuate Therapeutics), engineered cell therapy (Immusoft, IN8bio), gene therapy (Opus Genetics, Taysha Gene Therapies), AI-driven drug development (Lantern Pharma), medical devices (i-Lumen Scientific), recombinant proteins (Lung Therapeutics, Stream Biomedical), and macrophage immunotherapy (BobcatBio, SIRPant).

Differentiator

Problem solved

Functional benefit

Products and services

• Bios Partners Venture Capital Investment Services Life sciences venture capital investment services providing equity capital and active operational support to clinical-stage and preclinical biotech companies developing advanced therapeutics in the Central US, with revenue generated through management fees from limited partners and carried interest from portfolio exits.

Quantifiable outcome

• NIH funding of $3.36 per $1 of VC in Central US versus $0.57 in Western US and $0.68 in Northeastern US
• +2 more outcomes

Named customers16 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pappas Capital: Boutique life sciences venture firm based in Durham, NC, investing in early-stage biotech and medtech across the Southeastern US. Most direct geographic/scale analog to Bios Partners' Central US thesis.
• Hatteras Venture Partners: Durham, NC-based venture firm focused on seed and early-stage life sciences and tech startups, particularly from Mid-Atlantic research institutions. Closely matches Bios Partners' regional-specialist model.
• Santé Ventures: Austin-based venture firm specializing in early-stage healthcare and life sciences investments. Comparable regional focus and stage orientation to Bios Partners.
• 5AM Ventures: Boston/San Francisco-based life sciences venture firm focused on early-stage biotech platforms. Closely comparable in stage and modality focus, though larger and coastal.
• Atlas Venture: Cambridge, MA-based early-stage life sciences venture firm building biotech from inception. Closely comparable fund size and clinical-stage focus, despite coastal base.
• Cure Ventures: Early-stage life sciences venture firm supporting biotech founders with hands-on operational expertise. Closely matches Bios Partners' company-cultivation model.

Broad incumbents

• ARCH Venture Partners: Large, established life sciences venture firm investing across stages and modalities. Relevant as a benchmark for fundraising scale and exit economics, but far larger than Bios Partners.
• OrbiMed Advisors: Healthcare-dedicated investment firm across venture, growth and public equity. Comparable healthcare/life sciences mandate but at much greater scale and broader investment scope.
• Versant Ventures: Healthcare-focused venture firm investing in biotech, medtech and healthcare services. Comparable clinical-stage orientation but with significantly larger fund vehicles.
• Deerfield Management: Healthcare-focused investment firm spanning venture, public equities and structured financing. Provides a relevant reference point for clinical-stage biotech deal-making at scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bios Partners